Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study

Participants taking highest dose of tirzepatide experienced 91.2% time in range (71-180 mg/dL) and 72.6% time in tight target range (71-140 mg/dL) CGM sub-study achieved its primary and secondary endpoints INDIANAPOLIS , Sept. 30, 2021 /PRNewswire/ -- All three tirzepatide doses led to more time in